Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody

Cancer Immunology, Immunotherapy

Volumn 52, Issue 3, 2003, Pages 185-193

  Zhao, Chuanli ^a   Morgan, Max ^a   Haeryfar, S M Mansour ^a   Blay, Jonathan ^b   Hoskin, David W ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adhesion molecules; AK T cells; Chemo immunotherapy; Gene expression

Indexed keywords

CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY CD3; PACLITAXEL; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RESISTANCE;

EID: 0037385679     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0357-4     Document Type: Article

References (44)

1. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002) A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate cancinoma involving bone. Cancer 94: 1654
2. Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW, Ohashi PS (1997) Distinct roles for LFA-1 and CD28 during activation of naïve T cells: adhesion versus costimulation. Immunity 7: 549
3. Bass KK, Mastrangelo MJ (1998) Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47: 1
4. Bogdan C, Ding A (1992) Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52: 119
5. Chuang LT, Lotzov E, Heath J, Cook KR, Munkarah A, Morris M, Wharton JT (1994) Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res 54: 1286
6. Classen CF, Fulda S, Friesen C, Debatin KM (1999) Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. Leukemia 13: 410
7. Curtis JE, Minkin S, Minden MD, McCulloch EA (1996) A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukemia: preclinical cell culture studies. Br J Haematol 95: 354
8. Fitzpatrick L, Makrigiannis AP, Kaiser M, Hoskin DW (1996) Anti-CD3-activated killer T cells: interferon-gamma and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity. J Interferon Cytokine Res 16: 537
9. Gomez GG, Hutchinson RB, Kruse CA (2001) Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 27: 375
10. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA (2001) Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 98: 11737
11. Greil R (1998) Prognosis and management strategies of lymphatic neoplasias in the elderly. II. Hodgkin's disease. Oncology 55: 265
12. + TCR alpha beta and TCR gamma delta CTL in vivo. Immunol Rev 146: 82
13. Hoskin DW, Williams BA, Fitzpatrick L, Makrigiannis AP (1997) Cell biology and possible therapeutic applications of anti-CD3-activated killer-T cells. Int J Mol Med 1: 893
14. Jordan MA, Himes RH, Wilson L (1985) Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 45: 2741
15. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552
16. Julius MH, Simpson E, Herzenberg LA (1973) A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3: 645
17. Kirikae T, Ojima I, Ma Z, Kirikae F, Hirai Y, Nakano M (1998) Structural significance of the benzoyl group at the C-3;-N position of paclitaxel for nitric oxide and tumor necrosis factor production by murine macrophages. Biochem Biophys Res Commun 245: 698
18. Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR (1999) Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25: 279
19. Ling Y, Zhong Y, Perez-Soler R (2001) Disruption of cell adhesion and caspase-mediated proteolysis of beta and gamma-catenins and APC protein in paclitaxel-induced apoptosis. Mol Pharm 59: 593
20. Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW (2002) Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 20: 1989
21. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89: 783
22. Morgan M, Williams BA, Blay J, Hoskin DW (2002) Chemosensitization of T-47D breast carcinoma cells to TRAIL and Fas receptor-induced killing. Anticancer Res 22: 673
23. Mullins DW, Koci MD, Burger CJ, Elgert KD (1998) Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol Immunotoxicol 20: 473
24. + T cell proliferation requires phosphatidylinositol 3-kinase activity. J Immunol 166: 6523
25. Noble RA (1990) The discovery of the vinca alkaloids: chemotherapeutic agents against cancer. Biochem Cell Biol 68: 1344
26. Papadimitriou CA, Kouroussis C, Moulopoulos LA, Viahos G, Rodolakis A, Kiamouris C, Diakomanolis E, Gika D, Michalas S, Dimopoulos MA (2001) Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithilial ovarian cancer. Cancer 92: 1856
27. Perico N, Ostermann D, Bontempelli M, Morigi M, Amuchastegui CS, Zoja C, Akalin E, Sayegh MH, Remuzzi G (1996) Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol 7: 594
28. Poelman SM, Adeyanju MO, Robertson MA, Recant WM (2000) Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res 6: 4043
29. Posovszky C, Friesen C, Herr I, Debatin KM (1999) Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia 13: 400
30. Pucci B, Bellincampi L, Tafani M, Masciullo V, Melino G, Giordano A (1999) Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp Cell Res 252: 134
31. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF (1988) Characterization of functional surface structures on human natural killer cells. Adv Immunol 42: 181
32. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247
33. Rowinsky EK (1997) Paclitaxel pharmacology and other tumor types. Seminars Oncol 24: S19
34. Savas B, Cole SP, Tsuruo T, Pross HF (1996) P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. J Clin Immunol 16: 348
35. Savas B, Kerr PE, Ustun H, Cole SP, Pross HF (1998) Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinomas. Anticancer Res 18: 4355
36. Singer-Sam J, Robinson MO, Bellvè AR, Simon MI, Riggs AP (1990) Measurement by quantitative PCR of changes in HPRT, PGK-1, PGK-2, APRT, Mtase and Zfy gene transcripts during mouse spermatogenesis. Nucleic Acids Res 18: 1255
37. Tan G, Heqing L, Jiangbo C, Ming J, Yanhong M, Xianghe L, Hong S, Li G (2002) Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. Int J Cancer 97: 168
38. Tange S, Scherer MN, Graeb C, Weiss T, Justl M, Frank E, Andrassy J, Jauch K-W, Geissler EK (2002) The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 73: 216
39. Treichel RS, Olken S (1992) The relationship between multidrug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines. Int J Cancer 50: 305
40. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S (1990) The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144: 4579
41. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena J (1999) Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 274: 8208
42. White CM, Martin BK, Lee L-F, Haskill JS, Ting JP-Y (1998) Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 46: 104
43. Williams BA, Makrigiannis AP, Blay J, Hoskin DW (1997) Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells. Int J Cancer 73: 416
44. Zuckerman LA, Pullen L, Miller J (1998) Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation. J Immunol 160: 3259